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SUMMARY
Brazilian patients with benign prostatic hyperplasia were
randomised in a 12-week, double-blind, double-dummy
study to receive doxazosin gastrointestinal therapeutic sys-
tem (GITS) 4 mg q.i.d. (n ¼ 82) or tamsulosin 0.4
q.i.d. (n ¼ 83). Primary endpoints were the absolute and
percentage change from baseline in symptoms measured
by International Prostate Symptom Score (IPSS). Secon-
dary endpoints included IPSS, quality-of-life (QOL)
question from the IPSS, and questions 6 and 7 of the
Sexual Function Abbreviated Questionnaire (SFAQ) at
weeks 4 and 12. Doxazosin GITS and tamsulosin
improved IPSS with no signiﬁcant differences between
groups at week 12. During weeks 4–8, tamsulosin-treated
patients demonstrated a slower improvement
(p 0 0.001) in IPSS than doxazosin GITS-treated
patients. The proportion of satisﬁed patients was
observed earlier with doxazosin GITS (p ¼ 0.006) vs.
tamsulosin. At week 12, the proportion of patients with
little or no difﬁculty at ejaculation (Q6 of SFAQ) was
higher in the doxazosin GITS group (p ¼ 0.019). Both
treatments were well tolerated.
Keywords: Doxazosin; tamsulosin; benign prostatic
hyperplasia; international prostate symptom score; pros-
tate; ejaculation; gastrointestinal therapeutic system
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a non-malignant
enlargement of the prostate that can cause bladder obstruc-
tion leading to lower urinary tract symptoms (LUTS) as the
increased prostatic mass compresses the urethra and inhibits
urinary ﬂow (1). The incidence of BPH increases propor-
tionately with advancing age, with more than 70% of men
older than 70 years having histologic evidence of BPH (2).
Selective a1-adrenoceptor antagonists are considered the
ﬁrst line of standard pharmacologic treatment for patients
with BPH (3). These agents reduce urethral pressure (3)
and inhibit smooth muscle tone in the prostate and lower
urinary tract (4) by interrupting the motor sympathetic adr-
energic nerve supply to the prostate, reducing the pressure,
and improving the LUTS and urinary function in patients
with BPH (5).
Although all of the currently available a1-adrenoceptor
antagonists have demonstrated efﬁcacy in the treatment of
BPH, each is unique in its afﬁnity for various receptor sub-
types (a1A, a1B and a1D) (3) and, thus, the potential for both
beneﬁcial and adverse events (AEs). Doxazosin and tamsulo-
sin, both a1-adrenoceptor antagonists, have been shown to
provide the relief of symptomatic BPH with once-daily
dosing. The efﬁcacy of doxazosin, a long-acting, selective
a1-adrenoceptor antagonist, has been demonstrated by
improvements in urinary ﬂow rate and symptomatic measures
(e.g. nocturia, hesitancy, urgency and weak stream) (6,7).
Recently, a controlled-release formulation, doxazosin gastro-
intestinal therapeutic system (GITS), has been shown to
enhance the pharmacokinetic proﬁle and drug delivery rate,
minimising the ﬂuctuations and extending the time to peak
serum concentration compared with the doxazosin standard
formulation (8). Doxazosin GITS eliminates the need for
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Previous studies have shown doxazosin GITS to be effective
in reducing the symptoms of BPH when compared with pla-
cebo (9) and tamsulosin (10,11) or alfuzosin (7). Tamsulosin,
shown to be effective for the relief of symptomatic BPH, also
provides once-daily treatment in a modiﬁed-release capsule
and requires no titration (12). However, unlike doxazosin,
tamsulosin has been associated with abnormal ejaculation in
10–30% of patients in long-term studies (13,14).
The current clinical goal of therapy for patients with BPH
is to reduce the symptoms, with minimal AEs. The goal of
this study was to compare the efﬁcacy of the new formula-
tion of doxazosin 4 mg q.i.d. with tamsulosin 0.4 mg q.i.d.
for symptom improvement, changes in quality of life (QOL)
and in sexual function during 12 weeks of treatment.
MATERIALS AND METHODS
Study Design
This trial was a multicenter, randomised, double-blind,
double-dummy study comprised of two phases: a 2-week
washout phase and a 12-week active treatment phase. The
study was conducted in 10 Brazilian research centers from
13 November 2001 to 30 September 2002. The trial was
carried out in compliance with the Declaration of Helsinki
and with local laws and regulations relevant to the use of
new and non-approved therapeutic agents in patients.
Patients
All participating patients provided written informed con-
sent. Patients eligible for this clinical trial included male
ambulatory patients  50 years of age with a diagnosis of
BPH conﬁrmed by digital rectal examination and ultra-
sound, patients with International Prostate Symptom Score
(IPSS) 112, and patients able to receive oral treatment
with a1-adrenoceptor antagonists.
Those ineligible for this trial included patients with a
previous history of urological surgery (prostate, bladder or
urethra) and/or urine retention or catheter in the urinary
duct that, by the investigator’s sole discretion, may need
catheterisation within the next 3 months; patients with
prostate cancer, infection of the urinary tract or prostate-
speciﬁc antigen (PSA) 15 ng/ml; those with a clinical his-
tory suggesting serious cardiac or hepatic insufﬁciency,
hypotension or blood pressure 1180/110 mmHg; those
already receiving treatment for BPH; patients with a clinical
history of oesophagus or intestinal duct obstruction; those
receiving therapeutic drugs that may interfere with study
drugs (androgens, antiandrogens, diuretics, cholinergics,
anticholinergics and phytotherapy) within the previous
6 months; and patients with a history of alcohol or drug
abuse, concurrent serious disease or malignancy or signiﬁ-
cant psychological problems.
Study Methods
The initial visit (week 2) included the collection of baseline
information, such as demographics, medical history, phys-
ical examination, measurement of blood pressure and pulse
rate, assessment of the Qmax and urine volume, PSA test
and prostate ultrasound examination. Patients also answered
the IPSS questionnaire, including the question on QOL.
During the 12-week treatment phase, patients were rand-
omised to receive either 4-mg doxazosin GITS plus tam-
sulosin placebo q.i.d. or 0.4-mg tamsulosin plus doxazosin
placebo q.i.d.. Subsequent visits (weeks 0, 4, 8 and 12) also
included benign prostatic hyperplasia impact index (BII) on
QOL, questions one through ﬁve and 15 of the Interna-
tional Index of Erectile Function (IIEF), and questions six
and seven of the Sexual Function Abbreviated Questionnaire
(SFAQ). Additionally, Qmax, urine volume, blood pressure
and pulse rate were measured, and all AEs were recorded.
Efﬁcacy Assessments
Primary efﬁcacy endpoints were the absolute and percentage
change from baseline as measured by the IPSS at ﬁnal evalua-
tion. Secondary efﬁcacy endpoints included IPSS behaviour
over the length of the study (weeks 0, 4, 8 and 12), the
responses to the QOL question, the BII, the IIEF and SFAQ.
Safety parameters included AEs and assessment of vital signs.
Statistical Methods
The intent-to-treat (ITT) population included the patients
who took at least one dose of study medication and had both
a baseline measurement and at least one measure of efﬁcacy
variable analysed after the start of treatment. Results were con-
sidered statistically signiﬁcant at p   0.05. All tests were two-
tailed, and the SAS
  (Statistical Analysis System–SAS Institute,
Cary, NC, USA) system was used for statistical calculations.
Comparison of the primary efﬁcacy variables was made using
an ANCOVA model with baseline values as covariate for
absolute change from baseline and an ANOVA model for the
percentage change from baseline. Secondary variables were
analysed using the repeated measures ANOVA, adjusted for
baseline values, assuming an unstructured covariance matrix.
RESULTS
Patients
Of the 194 patients screened, 165 were randomised to
treatment. All randomised patients received study drug: 82
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sin (Table 1). At baseline, a medical history of hyperten-
sion (blood pressure 1140/90 mmHg) was recorded in 19
patients from the doxazosin GITS group and 20 patients
from the tamsulosin group. In the doxazosin GITS group,
65 patients completed the study. Fifteen patients violated
the protocol, and two were discontinued because of AEs.
In the tamsulosin group, 71 patients completed the study.
Seven patients violated the protocol, four were discontin-
ued because of AEs, and one patient withdrew informed
consent during the treatment period. Analyses were con-
ducted on the ITT population of 158 patients (76 in the
doxazosin GITS group and 82 in the tamsulosin group),
excluding the seven patients who had no postbaseline efﬁc-
acy data.
Efﬁcacy Assessments
The primary endpoint was the total amount and percent
change in IPSS at the ﬁnal visit (week 12). The total IPSS
showed signiﬁcant improvements from baseline in both
groups (p ¼ 0.001), as shown in Figure 1A. The difference
in IPSS change between the two groups was not signiﬁcant
(p ¼ 0.759) at endpoint. IPSS values were similar at weeks
4, 8 and 12 in patients receiving doxazosin GITS (Fig-
ure 1B). IPSS values in patients receiving tamsulosin
decreased signiﬁcantly between weeks 4 and 8
(p 0 0.0001).
When patients were asked, ‘If you were to stay with your
current urinary situation, how would you feel?’ the propor-
tion of satisﬁed patients in the doxazosin GITS group did
not vary over the study period (p ¼ 0.262). In contrast, the
responses of patients in the tamsulosin group changed signi-
ﬁcantly from weeks 4–8 (p ¼ 0.006), suggesting that the
number of satisﬁed patients in the doxazosin GITS group
increased earlier (Table 2). Although the response with tam-
sulosin at week 12 was numerically greater than the
response with doxazosin, there was no statistically signiﬁcant
difference between the two groups.
The BII scores decreased signiﬁcantly during the study
period in patients receiving both doxazosin GITS and tam-
sulosin (p ¼ 0.001), with no differences between the groups
(p ¼ 0.674) (Table 3). Although the mean values for Qmax
and urine volume were larger for tamsulosin at week 12
than for doxazosin, differences between the two groups were
Table 1 Baseline characteristics of the evaluated population
Characteristic
(n ¼ 158)
Doxazosin GITS
(n ¼ 82)
Tamsulosin
(n ¼ 83)
Age (years), mean   SD 62.6 (6.8) 61.7 (7.6)
Weight (kg), mean   SD 74.7   12.1 74.9   13.1
Height (cm), mean   SD 169.8   7.2 168.8   6.2
Race, n (%)
White 66 (80.5) 72 (86.7)
Black 11 (13.4) 11 (13.3)
Mixed race 4 (4.9) 0
Asian 1 (1.2) 0
GITS, gastrointestinal therapeutic system; SD, standard deviation.
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Figure 1 Effect of treatment on IPSS. (A) Percent change   SD
in total IPSS at week 12. (B) Mean   SE of IPSS at baseline,
weeks 4, 8, and 12. *p 0 0.01 tamsulosin week 4 vs. tamsulosin
week 8. GITS ¼ gastrointestinal therapeutic system; IPSS,
International Prostate Symptom Score
Table 2 Estimated proportion (%  SE) of patients satisﬁed with
their current condition based on the quality-of-life question
Group Visit
Satisﬁed patients
(%   SE)
Doxazosin GITS Week 4 42.57   5.75
Week 8 48.12   5.88
Week 12 53.06   5.75
Tamsulosin Week 4 31.33   5.27
Week 8 47.53   5.71
Week 12 56.59   5.50
GITS, gastrointestinal therapeutic system; SE, standard error.
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0.057; Table 3).
Patients were asked question 6 of the SFAQ: ‘In the past
30 days, how much difﬁculty have you had ejaculating
when you have been sexually stimulated?’ The proportion of
patients that answered ‘little difﬁculty’ or ‘no difﬁculty’ to
this question was signiﬁcantly higher (p ¼ 0.018) in the
doxazosin GITS group (87.14%) compared with those in
the tamsulosin group (71.33%) at the last visit (week 12)
(Figure 2). Patients were also asked question 7 of the
SFAQ: ‘In the past 30 days, how much did you consider
the amount of semen you ejaculate to be a problem for
you?’ The proportion of satisﬁed patients did not vary signi-
ﬁcantly between the two groups (p ¼ 0.109 for doxazosin
GITS; p ¼ 0.658 for tamsulosin). There were no signiﬁcant
differences between the doxazosin GITS group and tamsulo-
sin group for IIEF scores (p ¼ 0.156; Table 4).
Safety Assessments
Among the patients that received doxazosin GITS, 20.7%
(17) experienced at least 1 AE. In the tamsulosin group,
26.5% (22) reported at least one AE. No signiﬁcant difference
was found with regard to the proportion of patients that
experienced at least one AE in the two groups (p ¼ 0.383).
In the doxazosin GITS group, the most frequently reported
AEs are shown in Table 5. More patients in the doxazosin
group reported dizziness and headache (3; 3.7%) than in the
tamsulosin group (2; 2.4%). More patients in the tamsulosin
group reported abnormal ejaculation (4; 4.8%) than in the
Table 3 BII, Qmax, and urine volume during the trial (mean   SD)
Group Visit BII Qmax (ml/s) Urine volume (ml)
DOX GITS Baseline 5.85   2.55 (n ¼ 82) 11.50   5.63 (n ¼ 76) 230.34   111.89 (n ¼ 76)
Week 4 3.43   2.89 (n ¼ 74) 13.40   7.94 (n ¼ 71) 223.61   121.33 (n ¼ 71)
Week 8 3.10   2.78 (n ¼ 70) 13.01   5.57 (n ¼ 67) 228.65   127.56 (n ¼ 67)
Week 12 2.47   2.67 (n ¼ 75) 12.98   6.33 (n ¼ 72) 200.06   107.33 (n ¼ 72)
Tamsulosin Baseline 6.11   2.65 (n ¼ 82) 11.55   6.50 (n ¼ 78) 193.19   124.42 (n ¼ 78)
Week 4 3.56   2.82 (n ¼ 78) 13.48   9.27 (n ¼ 74) 236.06   149.25 (n ¼ 74)
Week 8 2.80   2.86 (n ¼ 75) 13.78   6.57 (n ¼ 71) 256.65   157.45 (n ¼ 71)
Week 12 2.43   2.83 (n ¼ 81) 13.68   7.56 (n ¼ 72) 245.79   142.74 (n ¼ 72)
BII, benign prostatic hyperplasia impact index; Qmax, maximum urine ﬂow rate; DOX, doxazosin; GITS, gastrointestinal therapeutic system; SD, standard
deviation.
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Figure 2 Percent of patients (mean   SE) with no or little
difﬁculty in ejaculation (question 6 of the Sexual Function
Abbreviated Questionnaire). *p ¼ 0.018 vs. tamsulosin. GITS,
gastrointestinal therapeutic system
Table 4 IIEF Score during the trial (mean   SD)
Group Visit IIEF
DOX GITS Baseline 17.95   8.84 (n ¼ 82)
Week 4 18.86   9.16 (n ¼ 74)
Week 8 17.37   9.67 (n ¼ 70)
Week 12 18.25   10.15 (n ¼ 75)
Tamsulosin Baseline 17.76   9.20 (n ¼ 82)
Week 4 18.36   9.06 (n ¼ 78)
Week 8 18.64   8.96 (n ¼ 75)
Week 12 19.81   9.28 (n ¼ 80)
IIEF, international index of erectile function; DOX, doxazosin; GITS, gas-
trointestinal therapeutic system; SD, standard deviation.
Table 5 Adverse events (AEs) occurring in  2% of patients*
AEs
Doxazosin GITS
(n ¼ 82)
Tamsulosin
(n ¼ 83)
Number of patients
with events, n (%)
17 (21) 22 (27)
Dizziness 3 (3.7) 2 (2.4)
Headache 3 (3.7) 2 (2.4)
Abnormal ejaculation 2 (2.4) 4 (4.8)
Chest pain 2 (2.4) 1 (1.2)
Decreased libido 2 (2.4) 0
Insomnia 2 (2.4) 0
Asthenia 1 (1.2) 2 (2.4)
Flu syndrome 0 2 (2.4)
Constipation 0 2 (2.4)
*Safety population included all patients that received at least one dose of
study medication. GITS, gastrointestinal therapeutic system.
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sulosin group reported retrograde ejaculation.
The number of patients who discontinued because of
AEs included four from the tamsulosin group and two from
the doxazosin GITS group. One patient from the doxazosin
GITS group experienced a serious AE, unstable angina,
which was considered related to the study drug. Two
patients from the tamsulosin group experienced serious AEs:
one patient had precordial pain related to the study drug;
the other patient had a cardiac valve disorder and symptoms
of myocardial infarction, which were considered unrelated
to the study drug.
DISCUSSION
The characteristics of various a1-adrenoceptor antagonists
have been compared in numerous placebo-controlled clinical
trials and have been shown to have similar efﬁcacy in the
management of BPH, improving the total symptom score
by approximately 30–45% (1). The current study showed
similar results, with both the doxazosin GITS group and
the tamsulosin group showing the signiﬁcant improvements
in total IPSS from baseline (p ¼ 0.001).
Patients receiving the tamsulosin in the current study
experienced a reduction in IPSS more slowly than those
receiving doxazosin GITS. This ﬁnding is supported by sim-
ilar results in other trials showing that doxazosin GITS pro-
duced improvements in symptoms early in treatment (9,15).
Also, these data are consistent with a recent report demon-
strating that doxazosin GITS was more effective in improv-
ing the BPH symptoms than tamsulosin after 4 weeks of
treatment (10).
Each of the a-blocking agents is considerably different in
terms of subtype binding and pharmacodynamics, which
may relate to their differences in potential for AEs (16).
Tamsulosin, for example, has been reported to result in
abnormal ejaculation with a frequency as high as 10% with
a dose of 0.4-mg q.i.d. and 26% with a dose of 0.8-mg
q.i.d. (13). In contrast, doxazosin GITS did not cause
abnormal ejaculation according to Kirby et al. (11). In the
current study, the proportion of patients that reported ‘little
difﬁculty’ or ‘no difﬁculty’ with ejaculation when sexually
stimulated was signiﬁcantly higher (p ¼ 0.018) in the doxa-
zosin GITS group (87.14%) compared with those in the
tamsulosin group (71.33%) at the last visit (week 12). Only
two (2.4%) of patients receiving doxazosin GITS reported
abnormal ejaculation, compared with four (4.8%) in the
tamsulosin group. None of the patients in the doxazosin
GITS group reported retrograde ejaculation, compared with
one (1.2%) in the tamsulosin group. We believe that the
more rapid onset and reduced incidence of sexual side
effects observed with doxazosin treatment are clinically sig-
niﬁcant and will probably improve compliance.
The general population of men with BPH is older, and
they often have concomitant diseases that require multiple
prescription drugs (17). Because doxazosin is also indicated
for hypertension, treatment with doxazosin GITS is especi-
ally efﬁcient in hypertensive patients with BPH symptoms,
yet normotensive patients experience no important reduc-
tions in blood pressure (7,18). Tamsulosin does not reduce
the blood pressure in a clinically signiﬁcant manner (14).
The recently published Medical Therapy of Prostatic
Symptoms (MTOPS) trial demonstrated that doxazosin sig-
niﬁcantly reduced the overall risk of clinical progression of
BPH over 4 years when compared with placebo (19). Clin-
ical progression in MTOPS was deﬁned as worsening of
symptoms, acute urinary retention, incontinence, urinary
tract infection or renal insufﬁciency (19).
In this study, unstable angina occurred in one of 82
patients taking doxazosin. In large clinical studies with dox-
azosin, including those lasting over a period of 4 years, AEs
were generally mild to moderate. Although reports of
angina have occurred during doxazosin use (20), it is not
distinguishable from symptoms of the underlying disease
that might have occurred without doxazosin use.
CONCLUSIONS
Doxazosin GITS and tamsulosin were similarly effective in
the treatment of symptomatic BPH after 12 weeks of
treatment and both treatments were well tolerated.
Improvement in symptoms was signiﬁcantly greater at
4 weeks in patients receiving doxazosin GITS vs. those
receiving tamsulosin. Additionally, the proportion of
patients reporting little or no difﬁculty in ejaculation was
greater in patients treated with doxazosin GITS than
patients treated with tamsulosin.
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